

# Simon Veedfald

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2776519/publications.pdf>

Version: 2024-02-01

32  
papers

843  
citations

623188

14  
h-index

476904

29  
g-index

32  
all docs

32  
docs citations

32  
times ranked

1150  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. <i>Diabetologia</i> , 2014, 57, 1919-1926.	2.9	156
2	The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. <i>American Journal of Physiology - Renal Physiology</i> , 2013, 304, G1117-G1127.	1.6	138
3	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. <i>Diabetes</i> , 2019, 68, 906-917.	0.3	118
4	Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. <i>European Journal of Endocrinology</i> , 2013, 169, 187-201.	1.9	51
5	Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. <i>American Journal of Physiology - Renal Physiology</i> , 2016, 310, G43-G51.	1.6	45
6	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e725-e738.	1.8	37
7	Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-5.	1.0	33
8	Gut hormone release after gastric bypass depends on the length of the biliopancreatic limb. <i>International Journal of Obesity</i> , 2019, 43, 1009-1018.	1.6	27
9	The anorexic hormone Peptide YY <sub>3-36</sub> is rapidly metabolized to inactive Peptide YY <sub>3-34</sub> in vivo. <i>Physiological Reports</i> , 2015, 3, e12455.	0.7	23
10	The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , 2015, 309, R544-R551.	0.9	22
11	GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report. <i>Cell Reports Medicine</i> , 2020, 1, 100006.	3.3	22
12	Hyperosmolar Duodenal Saline Infusion Lowers Circulating Ghrelin and Stimulates Intestinal Hormone Release in Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4409-4418.	1.8	17
13	GLP-1-induced renal vasodilation in rodents depends exclusively on the known GLP-1 receptor and is lost in prehypertensive rats. <i>American Journal of Physiology - Renal Physiology</i> , 2020, 318, F1409-F1417.	1.3	16
14	Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation. <i>Peptides</i> , 2015, 71, 229-231.	1.2	15
15	Ghrelin secretion in humans – a role for the vagus nerve?. <i>Neurogastroenterology and Motility</i> , 2018, 30, e13295.	1.6	14
16	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2017, 313, E284-E291.	1.8	13
17	The effect of acute dual SGLT1/SGLT2 inhibition on incretin release and glucose metabolism after gastric bypass surgery. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 318, E956-E964.	1.8	13
18	GIP and GLP-2 together improve bone turnover in humans supporting GIPR-GLP-2R co-agonists as future osteoporosis treatment. <i>Pharmacological Research</i> , 2022, 176, 106058.	3.1	13

#	ARTICLE	IF	CITATIONS
19	Acute effects of glucagon-like peptide-1, GLP-1<sub>9-36 amide</sub>, and exenatide on mesenteric blood flow, cardiovascular parameters, and biomarkers in healthy volunteers. <i>Physiological Reports</i> , 2017, 5, e13102.	0.7	12
20	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020, 105, e502-e510.	1.8	12
21	Subcutaneous GIP and GLP-2 inhibit nightly bone resorption in postmenopausal women: A preliminary study. <i>Bone</i> , 2021, 152, 116065.	1.4	8
22	Intestinal sensing and handling of dietary lipids in gastric bypassâ€‘operated patients and matched controls. <i>American Journal of Clinical Nutrition</i> , 2020, 111, 28-41.	2.2	7
23	On measurements of glucagon secretion in healthy, obese, and Roux-en-Y gastric bypass operated individuals using sandwich ELISA. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 2022, 82, 75-83.	0.6	7
24	Colonic Lactulose Fermentation Has No Impact on Glucagon-like Peptide-1 and Peptide-YY Secretion in Healthy Young Men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, 77-87.	1.8	6
25	CCKâ€‘1 and CCKâ€‘2 receptor agonism do not stimulate GLPâ€‘1 and neurotensin secretion in the isolated perfused rat small intestine or GLPâ€‘1 and PYY secretion in the rat colon. <i>Physiological Reports</i> , 2020, 8, e14352.	0.7	5
26	The insulinotropic effect of exogenous glucagonâ€‘like peptideâ€‘1 is not affected by acute vagotomy in anaesthetized pigs. <i>Experimental Physiology</i> , 2016, 101, 895-912.	0.9	4
27	Entero-Pancreatic Hormone Secretion, Gastric Emptying, and Glucose Absorption After Frequently Sampled Meal Tests. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e188-e204.	1.8	4
28	Neurotensin secretion after Rouxâ€‘enâ€‘Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty. <i>Neurogastroenterology and Motility</i> , 2021, , e14210.	1.6	2
29	Restoration of enteroendocrine and pancreatic function after internal hernia and short bowel syndrome in a young woman with gastric bypass - a 2-year follow-up. <i>Physiological Reports</i> , 2018, 6, e13686.	0.7	1
30	Glucose homeostasis and the gastrointestinal tract. , 2019, , 3-19.		1
31	Pancreatic polypeptide: A potential biomarker of glucoseâ€‘dependent insulinotropic polypeptide receptor activation in vivo. <i>Diabetic Medicine</i> , 2021, 38, e14592.	1.2	1
32	Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes. <i>European Journal of Case Reports in Internal Medicine</i> , 2021, 8, 002352.	0.2	0